Pubblicazioni

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

2015 - THE LANCET ONCOLOGY

Cremolini, C; Loupakis, F; Antoniotti, C; Lupi, C; Sensi, E; Lonardi, S; Mezi, Silvia; Tomasello, G; Ronzoni, M; Zaniboni, A; Tonini, G; Carlomagno, C; Allegrini, G; Chiara, S; D'Amico, M; Granetto, C; Cazzaniga, M; Boni, L; Fontanini, G; Falcone, A. 1. 6.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

2015 - THE LANCET ONCOLOGY

Topp, Ms; GÃ¶kbuget, N; Stein, As; Zugmaier, G; O'Brien, S; Bargou, Rc; Dombret, H; Fielding, Ak; Heffner, L; Larson, Ra; Neumann, S; Foa, Roberto; Litzow, M; Ribera, Jm; Rambaldi, A; Schiller, G; BrÃ¼ggemann, M; Horst, Ha; Holland, C; Jia, C; Maniar, T; Huber, B; Nagorsen, D; Forman, Sj; Kantarjian, H. M.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

2015 - THE LANCET ONCOLOGY

Efficace, F; Gaidano, G; Breccia, M; Voso, Mt; Cottone, F; Angelucci, E; Caocci, G; Stauder, R; Selleslag, D; Sprangers, M; Platzbecker, U; Ricco, A; Sanpaolo, G; Beyne-Rauzy, O; Buccisano, F; Palumbo, Ga; Bowen, D; Nguyen, K; Niscola, P; Vignetti, M; Mandelli, F.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4). A double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 - THE LANCET ONCOLOGY

Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C; Hart, Lowell L; Jones, Robert; Mcdermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; Maclean, David B; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I; Dreicer, Robert; Webb, Iain J; de Wit, Ronald; Collaborators, ; Tubaro, Andrea